Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Medical Xpress

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating them with the antibody-drug conjugate (ADC) inotuzumab ozogamicin. ...

전문 보기

이 뉴스, 어떠셨어요?

한 번의 탭으로 반응을 남겨요 · 로그인 불필요

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Researchers chart a genetic path to diagnosing pulmonary fibrosis and predicting outcomes

Study finds sharing tax numbers boosts transparency, not confusion, for investors

Satellite record reveals US tidal wetland productivity rose 6% in 20 years

Medical Xpress의 다른 기사

Nearly 20% of new moms have anxiety or depression, but a promising psychedelic treatment is on the horizon

Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy

Five-agent AI team could speed clinical trial design using real-world patient records